Summary
The absorption kinetics of intranasal salmon calcitonin were assessed in 4 normal subjects and 9 patients with Klinefelter's syndrome. After administration, absorption occurred within 5 minutes. There was a highly significant correlation between the amount administered and the amount absorbed (r=−0.83,P<0.0005).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gennari C, Chierichetti SM, Bigazzi S (1985) Comparative effect on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464
Gruber HE, Ivey JL, Baylink DJ (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303
Mazzuoli GF, Pusseir M, Gennari C (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8
Kurose H, Seino Y, Shima M, Tanaka H, Ishida M, Yamaoka K, Yabunchi H (1987) Intranasal absorption of salmon calcitonin. Calcif Tissue Int 41:249–251
Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106:354–361
Foresta C, Scanelli G, Zanatta GP, Busuardo B, Scandellari C (1987) Reduced calcitonin reserve in young hypogonadic osteoporotic men. Horm Metab Res 19(6):275–277
Schwartz CM, Young MA (1988) Male hypogonadism: risks for myocardial infarction and bone fracture. Compr Ther 14(4):21–24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pun, K.K., Chan, W.L., Lau, P. et al. Absorption of intranasal salmon calcitonin in normal subjects and hypogonadic men. Calcif Tissue Int 46, 130–132 (1990). https://doi.org/10.1007/BF02556097
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02556097